Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Small Cell Lung Carcinoma 1Sezary Syndrome 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Prolymphocytic 1Leukemia, Hairy Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1Intraocular Lymphoma 1Immunoblastic Lymphadenopathy 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Dexamethasone 33Cyclophosphamide 28Melphalan 26Specimen Handling 24Biopsy 24Bortezomib 23Magnetic Resonance Spectroscopy 17Calcium Dobesilate 17fludarabine phosphate 15Lenalidomide 15Filgrastim 15Vincristine 12Prednisone 12Peripheral Blood Stem Cell Transplantation 12sargramostim 9dexamethasone acetate 9dexamethasone 21-phosphate 9carfilzomib 9auricularum 9Doxorubicin 9fludarabine 8Thalidomide 8Interferon-alpha 7Cyclosporine 7Busulfan 7trametinib 6Rituximab 6Etoposide 6ixazomib 5Sirolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Multiple Myeloma × obatoclax × Clear all
NCT00719901 2015-01-12

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1/2 Terminated
11 enrolled 9 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡